Ensemble Pharmacophore Meets Molecular Docking: A Novel Screening Approach for the Identification of B-Raf Kinase Inhibitors
DOI:
https://doi.org/10.48048/tis.2023.6403Keywords:
B-Raf kinase inhibitors, Pharmacophore modeling, PharmaGist, ZINCPharmer, ADME, Binding energyAbstract
In US about 106110 diagnosed as melanomas, 7,180 people expected to die due to melanoma. B-RAF is a cytoplasmic serine - threonine kinase that is found in a mutated form in melanoma and colorectal cancer. Sorafenib was initially introduced as a B-RAF inhibitor in melanoma. Hence it is taken as a pivot molecule in our study. Four potent B-Raf kinase inhibitors (Sorafenib, Regorafenib, N-desmethyl sorafenib & Donafenib) are used to build a pharmacophore model with ‘PharmaGist webserver’ which generated a 5-point hypothesis. The best model with score of 27.780, was used to screen the Zinc database of ZINCPharmer web server to obtain similar pharmacophore hits. By applying filters like Lipinski rule, RMSD criteria in ZINCPharmer top ten hits were identified. Subsequently, molecular docking was performed on wild (1UWH) and mutated (3IDP) B-Raf kinase protein targets by using GLIDE 5.6 (Schrödinger), to prioritize top lead molecules. Further these molecules are subjected to ADME Properties Prediction by Qik Prop module. Among ten, nine molecules have glide scores in the range nearer to the standard molecule i.e., Sorafenib. Finally, we conclude that ZINC02853810 may act as a powerful inhibitor against both wild and mutant type B-Raf kinase as it has highest glide scores than the Standard.
GRAPHICAL ABSTRACT
Downloads
References
A Vivek, MD Kar and BS Kumar. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur. J. Med. Chem. 2016; 10, 314-41.
UG Bhat, PA Zipfel, DS Tyler and AL Gartel. Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle. 2008; 7, 1851-5.
S Dubey and A Roulin. Evolutionary and biomedical consequences of internal melanins. Pigment Cell Melanoma Res. 2014; 27, 327-38.
V Dembitsky and A Kilimnik. Anti-melanoma agents derived from fungal species. Mathews J. Pharm. Sci. 2016; 1, 002.
Y Yu-Shun, Z Fei, T Dan-Jie, Y Yong-Hua and Z Hai-Liang. Modification, biological evaluation and 3D QSAR studies of novel 2-(1,3-Diaryl- 4,5-Dihydro-1H-Pyrazol-5- yl) phenol derivatives as inhibitors of B-Raf Kinase. PLoS One 2014; 9, e95702.
AB Umar, A Uzairu, GA Shallangwa and S Uba. In silico evaluation of some 4-(quinolin-2- yl) pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions. Futur. J. Pharm. Sci. 2020; 61, 1-10.
A Vivek, MD Kar and BS Kumar. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. Eur. J. Med. Chem. 2017; 125, 299-314.
T Knight and JAE Irving. Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukaemia and its therapeutic targeting. Front. Oncol. 2014; 160, 1-10.
HB El-Nassan. Recent progress in the identification of BRAF inhibitors as anti-cancer agents. Eur. J. Med. Chem. 2014; 72, 170-205.
A Nourry, A Zambon, L Davies, I Niculescu-Duvaz, HP Dijkstra, D Me´nard, C Gaulon, D Niculescu-Duvaz, BMJM Suijkerbuijk, F Friedlos, HA Manne, R Kirk, S Whittaker, R Marais and CJ Springer. BRAF inhibitors based on an imidazo[4, 5]pyridin-2- one scaffold and a meta substituted middle ring. J. Med. Chem. 2010; 53, 1964-78.
PTC Wan, MJ Garnett, SM Roe, S Lee, D Niculescu-Duvaz, VM Good, CM Jones, CJ Marshall, CJ Springer, D Barford and R Marais. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116, 855-67.
A Yong, W Shao-Teng, C Tang, S Ping-Hua and S Fa-Jun ong. 3D-QSAR and docking studies on pyridopyrazinones as BRAF inhibitors. Med. Chem. Res. 2011; 20, 1298-317.
W Lu, Z Qing, Z Gaoyuan, Z Zhang, Y Zhi, L Zhang, T Mao, X Zhou, Y Chen, T Lu and W Tang. Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. Eur. J. Med. Chem. 2017; 15, 3455-65.
K Zoi, G Evripidis and PI Poulikakos. New perspectives for targeting RAF Kinase in human cancer. Nat. Rev. Cancer. 2017; 17, 679-91.
W Lu, Z Gaoyuan, Z Qing, C Duan, Y Zhang, Z Zhang, Y Zhou, T Lu and W Tang. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. Eur. J. Med. Chem. 2017; 15, 3455-65.
W Yang, Ya Chen, X Zhou, Y Gu, W Qian, F Zhang, W Han, T Lu and W Tang. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. Eur. J. Med. Chem. 2015; 89, 581-96.
PS Reddy, SS Kanth and M Vijjulatha. Discovery and design of new PI3K inhibitors through pharmacophore-based virtual screening, molecular docking, and binding free energy analysis. Struct. Chem. 2018; 29, 1753-66.
S Usha. Pharmacophore-based database searching of kinase-inhibitor mimetic molecular hits. J. Bio. Innov. 2016; 5, 446-63.
RA Friesner, JL Banks and RB Murphy. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004; 47,1739-49.
PS Reddy, SS Kanth and M Vijjulatha. Molecular dynamics and MM/GBSA integrated protocol probing the correlation between biological activities and binding free energies of HIV-1 TAR RNA inhibitors. J. Biomol. Struct. Dyn. 2018; 36, 486-503.
J Li, R Abel, K Zhu, Y Cao, S Zhao and RA Friesner. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins 2011; 79, 2794-812.
WC Still, A Tempczyk, RC Hawley and T Hendrickson. Semi analytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990; 112, 6127-9.
SA Starosyla, GP Volynets, VG Bdzhola, AG Golub, MV Protopopov and SM Yarmoluk. ASK1 pharmacophore model derived from diverse classes of inhibitors. Bioorg. Med. Chem. Lett. 2014; 24, 4418-23.
O Dror, DS Duhovny, Y Inbar, R Nussinov and JH Wolfson. Novel approach for efficient pharmacophore-based virtual screening: Method and applications. J. Chem. Inf. Model. 2009; 49, 2333-43.
S Sivaraj, RA Siva, M Karunagaran, K Yuvaraj, M Ismail, V Muralidharan, S Rangaraj and A Suguna. Bedaquiline: A potential inhibitor of COVID-19 main protease based on molecular docking. Int. J. Res. Pharmacol. Pharmacother. 2020; 9, 136-144.
R Zainab, A Kaleem, BM Ponczek, R Abdullah, M Iqtedar and CD Hoessli. Finding inhibitors for PCSK9 using computational methods. PLoS One 2021; 16, 1-18.
R Agrawal, P Jain and SN Dikshit. Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents. Comb. Chem. High Throughput Screen. 2012; 15, 849-76.
S Sivaraj, RA Siva, M Karunagaran, K Yuvaraj, M Ismail, V Muralidharan, S Rangaraj and A Suguna. Bedaquiline - A potential inhibitor of COVID-19 main protease based on molecular docking. Int. J. Res. Pharmacol. Pharmacother. 2020; 9, 136-44.
B Srilata, I Ramesh, S Sree Kanth and M Vijjulatha. Rational design of methicillin resistance staphylococcus aureus inhibitors through 3D-QSAR, molecular docking and molecular dynamics simulations. Comput. Biol. Chem. 2018; 73, 95-104.
V Tamalapakula, SK Balabadra, RK Munnaluri and V Manga. InSilico Design: Those accentuate assembly of HIV-1 capsid. Nov. Appro. Drug Des. Dev. 2017; 2, 555600.
K Kalpana, SR Kumar and N Ravindra. Identification of novel anti-cryptosporidial inhibitors through a combined approach of pharmacophore modeling, virtual screening, and molecular docking. Inform. Med. Unlocked 2021; 24, 100583.
EC Padilha, RB Serafim, DYR Sarmiento, CF Santos, CBR Santos and CHTP Silvab. New PPARα/γ/δ optimal activator rationally designed by computational methods. J. Braz. Chem. Soc. 2016; 27, 1636-47.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
